Dana-Farber’s Breast Oncology Center

Patient-centered care, clinical trials & translational research on breast cancer @DanaFarber and @HarvardMed. Appts: 877-442-3324, Clinical trials: 877-338-7425

[Dana-Farber @DanaFarber]

Congratulations to Judy E. Garber, MD, MPH, on receiving the 2026 Basser Global Prize from @BasserBRCA, which recognizes a leading scientist who has advanced BRCA1 and BRCA2-related research. Through her research and clinical leadership, Dr. Garber has helped translate discoveries about BRCA-related cancers into treatments and care guidelines that are now used around the world. Learn more: https://t.co/a4LeRX0FzM

[Community Health Media @CHMediaHub]

Are we stopping T-DXd + pertuzumab too soon?

Drs. Paolo Tarantino (@PTarantinoMD) and Seth Wander make a point that may surprise many oncologists. With T-DXd + pertuzumab, the median time to maximum tumor reduction is about 11 to 12 months, and some patients take even longer.

Many patients are labeled a partial response when they’re actually still on their way to something deeper.

That challenges how many have practiced for years. Their message is that we shouldn’t be so quick to pull the combination after an arbitrary number of induction cycles.

Full conversation here: https://t.co/sdGBm2LgwF

💬 When do you switch to maintenance with T-DXd + pertuzumab?

[Dana-Farber @DanaFarber]

.@DrHBurstein was recently appointed Faculty Associate Dean for Admissions in the Program in Medical Education at @harvardmed. Please join us in congratulating him on this new appointment.

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

We are now enrolling to the #ERADICATE study!​

This is a phase Ib/II study of #Elacestrant in combination with #TrastuzumabDeruxtecan (T-DXd) for patients with CDK4/6 inhibitor and endocrine-resistant HR+/HER2-low or HER2-ultralow metastatic #BreastCancer.​

To learn more about the #ERADICATE study, call 877-338-7425 or visit https://t.co/SiyP47T6tI​
PI: @KristinaFanucci #MetastaticBreastCancer #MBC #ClinicalTrial #BreastCancerResearch ​#TDXd

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

Dr. Harold Burstein (@DrHBurstein) sharing updates from #ESMO26 in our Breast Oncology Seminar Series (BOSS). #BreastCancer

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

The DATO-BASE phase 2 trial is still actively recruiting patients in:

🔹 Cohort A: ER+/HER2− breast cancer with brain metastases

🔹 Cohort B: TNBC with brain metastases

More info & eligibility:
https://t.co/gNiwtxZv0q

@PTarantinoMD @nlinmd

[Paolo Tarantino @PTarantinoMD]

Patients with CNS disease need more. Need better therapies. Like novel ADCs!

DATO-Base is the first trial I designed when I moved to DFCI, mentored by @drsarahsam & @nlinmd. It tests Dato-DXd for CNS disease, with the LMD cohort fully accrued.

Results coming soon — stay tuned!

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

Hear from Ana Garrido-Castro, MD, and Filipa Lynce, MD (@FilipaLynce), on recent treatment developments and research in metastatic #TNBC.
This session is part of the 2026–2027 EMBRACE Metastatic #BreastCancer Forum Series and includes a Q&A moderated by Sahara Baral. #MetastaticBreastCancer #BreastCancerResearch #TripleNegativeBreastCancer

https://t.co/1PB3dDQ273

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

Check out this recent review 👉Right-sizing treatment for HER2-positive breast cancer: evolving algorithms across the disease continuum.

https://t.co/V1XHa42W5G

@PTarantinoMD @ValenzaCarmine @elia_segui @nlinmd @curijoey @adawaksmd @stolaney1 #BreastCancer

[Nancy Lin, MD @nlinmd]

Excited to kick off our annual EMBRACE webinar series designed to educate and empower people living with metastatic breast cancer …

To see recordings from 2025-2026 and check out what is coming up in 2026-2027:

https://t.co/3wOFXLfgA9

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

Check out this @JNCI_Now national cancer database study 👉 21-Gene recurrence score assay in pN2-3 Early-Stage #BreastCancer.
https://t.co/ijFnaFRIbH
@ValenzaCarmine @darioT_ @GuiNaderMarta @dr_laurad @stolaney1 @AnnPartridgeMD @curijoey @DrHBurstein #JosePabloLeone

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

Adrienne Waks, MD (@adawaksmd), and Ilana Schlam, MD (@IlanaSchlam), present updates on current treatment approaches and emerging research in HER2-positive #MetastaticBreastCancer as part of the 2026–2027 EMBRACE #MBC Forum Series. Watch here:
https://t.co/dwG4RQavGp

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

Here’s the most recent #BreastCancer Research Digest-a summary of last week’s publications from select high-impact journals (October 30th - November 6th, 2026). #ClinicalResearch #CancerTreatment #BCSM #BreastCancerResearch #BreastCancer

[Paolo Tarantino @PTarantinoMD]

One of the most impressive roundtables I’ve ever joined.

The goal: navigating the brave new post-DB09/05/11 world.

Featuring Sara Hurvitz, Neil Iyengar, Heather McArthur, Erika Hamilton, Tiffany Traina, Jason Mouabbi and myself.

Watch it here: https://t.co/Wd0np9kyWf #ESMO26

[Ada Waks @adawaksmd]

Congrats @michelle_li and excited for you to present these updated results from MARGOT/TBCRC052!!! @TheTBCRC

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

We are leading a study on the use of #ctDNA NGS and MRD Assays in Clinical Practice.
If you are a licensed clinician who treats patients with #BreastCancer, help us better understand current practice patterns and perceptions regarding the use of circulating tumor DNA (ctDNA) standard next-generation sequencing (#NGS) assays and minimal residual disease (#MRD) assays in breast cancer, across both early-stage and metastatic settings.

Our goal is to identify how these tools are currently being used, the perceived barriers to their implementation, and the evidence or resources needed to support the integration of ctDNA testing into routine clinical practice. Thank you in advance for taking our short (10-15 minutes) questionnaire!

👉Link: https://t.co/eG5gZbc2cE

For more info: [email protected] #BreastCancerResearch #BloodTest #BloodBiopsy PI: Ilana Schlam (@IlanaSchlam)

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

You can now watch the recording of our live #BreastCancerBreakthroughs webinar where @DanaFarber experts discuss important #BreastCancer research presented at #ESMO26.
@DrHBurstein @stolaney1 @elmayermd @antgiorda #AnnGarridoGastro
https://t.co/Ru2TqDA1dQ

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

📽️Watch: The 2026–2027 EMBRACE Metastatic Breast Cancer Forum Series: Updates in ER-Positive #MBC.

Kristina Fanucci, MD, MHS, and Antonio Giordano, MD, PhD (@antgiorda), discuss treatment advances and research updates, followed by a Q&A moderated by Molly Skeffington. #MetastaticBreastCancer #BreastCancer #ERPositive

https://t.co/yAIrEUZXym

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

Now available in @jitcancer 👉PARP1-selective inhibitor DSB1559 demonstrates superior efficacy and antitumor immunity in #TripleNegativeBreastCancer

🔓https://t.co/5PIykFDkJI

@Carlos_Wagner1 @DanMichaud16 @FilipaLynce @GShapiroMDPhD @JennGuerriero #TNBC #BreastCancer #PARP1

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

Check out this recent systematic review and meta-analysis of neoadjuvant #AntibodyDrugConjugates for early-stage breastcancer.
🔓https://t.co/NWKwRRi03r
@ruiz_simoes @RafaelLaraNohmi @PTarantinoMD #ADCs #eBC #BreastCancer

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

Dr. Ana Garrido-Castro will be moderating the #TNBC session a the Bridging the Gaps in #BreastCancer meeting next Tuesday in NYC. And the results of these @OncLive polls will drive part of the discussion, bringing real-world perspectives and insights to the table. Share your thoughts and help shape the conversation! ⬇️

[OncLive.com @OncLive]

When choosing an ADC for 1L PD-L1–negative mTNBC, which toxicity weighs most in your decision?